SG10201510668UA - Alkoxy pyrazoles as soluble guanylate cyclase activators - Google Patents
Alkoxy pyrazoles as soluble guanylate cyclase activatorsInfo
- Publication number
- SG10201510668UA SG10201510668UA SG10201510668UA SG10201510668UA SG10201510668UA SG 10201510668U A SG10201510668U A SG 10201510668UA SG 10201510668U A SG10201510668U A SG 10201510668UA SG 10201510668U A SG10201510668U A SG 10201510668UA SG 10201510668U A SG10201510668U A SG 10201510668UA
- Authority
- SG
- Singapore
- Prior art keywords
- guanylate cyclase
- soluble guanylate
- cyclase activators
- pyrazoles
- alkoxy
- Prior art date
Links
- -1 Alkoxy pyrazoles Chemical class 0.000 title 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title 1
- 239000003119 guanylate cyclase activator Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261697899P | 2012-09-07 | 2012-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201510668UA true SG10201510668UA (en) | 2016-01-28 |
Family
ID=49170904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201510668UA SG10201510668UA (en) | 2012-09-07 | 2013-09-03 | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| SG11201500861QA SG11201500861QA (en) | 2012-09-07 | 2013-09-03 | Alkoxy pyrazoles as soluble guanylate cyclase activators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500861QA SG11201500861QA (en) | 2012-09-07 | 2013-09-03 | Alkoxy pyrazoles as soluble guanylate cyclase activators |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8906904B2 (en) |
| EP (1) | EP2892891B1 (en) |
| JP (1) | JP5970134B2 (en) |
| KR (1) | KR101692707B1 (en) |
| CN (1) | CN104619695B (en) |
| AP (1) | AP2015008231A0 (en) |
| AR (1) | AR092869A1 (en) |
| AU (1) | AU2013312931B2 (en) |
| BR (1) | BR112015004529B1 (en) |
| CA (1) | CA2880494C (en) |
| CL (2) | CL2015000255A1 (en) |
| CY (1) | CY1122610T1 (en) |
| DK (1) | DK2892891T3 (en) |
| EA (1) | EA027244B1 (en) |
| EC (1) | ECSP15012804A (en) |
| ES (1) | ES2748798T3 (en) |
| GE (1) | GEP20176631B (en) |
| HR (1) | HRP20191755T1 (en) |
| HU (1) | HUE046996T2 (en) |
| IL (1) | IL236987A (en) |
| LT (1) | LT2892891T (en) |
| MA (1) | MA37891B1 (en) |
| MD (1) | MD4425C1 (en) |
| MX (1) | MX338887B (en) |
| NZ (1) | NZ703989A (en) |
| PE (1) | PE20151001A1 (en) |
| PH (1) | PH12015500457B1 (en) |
| PL (1) | PL2892891T3 (en) |
| PT (1) | PT2892891T (en) |
| RS (1) | RS59394B1 (en) |
| SG (2) | SG10201510668UA (en) |
| SI (1) | SI2892891T1 (en) |
| TN (1) | TN2015000054A1 (en) |
| TW (1) | TWI586661B (en) |
| UA (1) | UA115881C2 (en) |
| UY (1) | UY35012A (en) |
| WO (1) | WO2014039434A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA115881C2 (en) * | 2012-09-07 | 2018-01-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| TW201625584A (en) | 2014-07-02 | 2016-07-16 | 諾華公司 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators |
| DK3172202T3 (en) | 2014-07-22 | 2020-04-27 | Boehringer Ingelheim Int | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE |
| HK1254636A1 (en) | 2015-12-18 | 2019-07-26 | Novartis Ag | Indane derivatives and the use thereof as soluble guanylate cyclase activators |
| EP3525778A1 (en) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Use of activators and stimulators of sgc comprising a beta2 subunit |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| JP7314173B2 (en) | 2018-04-30 | 2023-07-25 | バイエル アクチェンゲゼルシャフト | Use of sGC activators and sGC stimulants for the treatment of cognitive impairment |
| MX2020012230A (en) | 2018-05-15 | 2021-01-29 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization. |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| EP3820470B1 (en) * | 2018-07-12 | 2024-09-11 | Boehringer Ingelheim International GmbH | Alkoxy pyrazoles as soluble guanylate cyclase activators for use in treating portal hypertension |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| PL4043451T3 (en) * | 2019-10-18 | 2024-06-10 | Fmc Corporation | METHODS OF PRODUCING THE INTERMEDIATE IN THE SYNTHESIS OF 5-BROMO-2-(3-CHLOROPYRIDIN-2-YLO)-2H-PYRAZOLO-3-CARBOXYLIC ACID |
| CN112079712B (en) * | 2020-09-18 | 2022-12-13 | 江苏美迪克化学品有限公司 | Preparation method of p-vinyl salicylic acid |
| EP4259617B1 (en) * | 2020-12-10 | 2024-10-23 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| TW202402274A (en) | 2022-03-21 | 2024-01-16 | 德商百靈佳殷格翰國際股份有限公司 | Soluble guanylate cyclase activators for treating portal hypertension |
| JP2025518350A (en) | 2022-06-09 | 2025-06-12 | バイエル・アクチエンゲゼルシヤフト | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women - Patents.com |
| WO2024097316A1 (en) | 2022-11-04 | 2024-05-10 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators for treating systemic sclerosis |
| EP4630113A1 (en) | 2022-12-09 | 2025-10-15 | Boehringer Ingelheim International GmbH | Solid forms of a sgc activator |
| WO2025036839A1 (en) | 2023-08-16 | 2025-02-20 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators for treating clinically significant portal hypertension and decompensated cirrhosis |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| WO2002026712A2 (en) | 2000-09-29 | 2002-04-04 | Millennium Pharmaceuticals, Inc. | Quaternary amines and related inhibitors of factor xa |
| AR031176A1 (en) | 2000-11-22 | 2003-09-10 | Bayer Ag | NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE |
| CN1568564A (en) | 2000-11-22 | 2005-01-19 | 维思克斯公司 | Temperature actuated positioning device for non-linear optical elements |
| GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
| ZA200504898B (en) * | 2002-12-20 | 2006-11-29 | Pharmacia Corp | Acyclic pyrazole compounds |
| MX2008000779A (en) | 2005-07-18 | 2008-02-21 | Bayer Healthcare Ag | Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders. |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| WO2008138483A1 (en) * | 2007-05-12 | 2008-11-20 | Bayer Schering Pharma Aktiengesellschaft | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS |
| BRPI0816382A2 (en) | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | COMPOUND, COMPOSITION, AND METHODS TO ACTIVATE SOLUBLE GUANILATE CYCLASE AND TO TREAT OR PREVENT DISEASES |
| JP5487107B2 (en) * | 2007-10-05 | 2014-05-07 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamide in the treatment of pain |
| WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| TW200938529A (en) * | 2007-12-03 | 2009-09-16 | Smithkline Beecham Corp | Compounds |
| JP5432890B2 (en) * | 2008-04-04 | 2014-03-05 | 武田薬品工業株式会社 | Heterocyclic derivatives and uses thereof |
| WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| WO2010015652A2 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US20120022028A1 (en) * | 2009-01-17 | 2012-01-26 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction |
| AU2010218224B2 (en) | 2009-02-26 | 2013-06-27 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| EP2531187B1 (en) * | 2010-02-05 | 2015-08-12 | Adverio Pharma GmbH | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| MA34249B1 (en) * | 2010-05-26 | 2013-05-02 | Bayer Ip Gmbh | USE OF SGC STIMULATORS, SGC ACTIVATORS, ONLY AND IN ASSOCIATION WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROMERMIA |
| EP2585055A1 (en) | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2683710B1 (en) | 2011-03-10 | 2017-07-19 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
| WO2013025425A1 (en) | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| UA115881C2 (en) * | 2012-09-07 | 2018-01-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Alkoxy pyrazoles as soluble guanylate cyclase activators |
-
2013
- 2013-09-03 UA UAA201503030A patent/UA115881C2/en unknown
- 2013-09-03 CN CN201380046266.3A patent/CN104619695B/en active Active
- 2013-09-03 PT PT137626669T patent/PT2892891T/en unknown
- 2013-09-03 HU HUE13762666A patent/HUE046996T2/en unknown
- 2013-09-03 DK DK13762666.9T patent/DK2892891T3/en active
- 2013-09-03 BR BR112015004529-4A patent/BR112015004529B1/en active IP Right Grant
- 2013-09-03 HR HRP20191755TT patent/HRP20191755T1/en unknown
- 2013-09-03 MD MDA20150019A patent/MD4425C1/en active IP Right Grant
- 2013-09-03 WO PCT/US2013/057826 patent/WO2014039434A1/en not_active Ceased
- 2013-09-03 EP EP13762666.9A patent/EP2892891B1/en active Active
- 2013-09-03 MX MX2015002807A patent/MX338887B/en active IP Right Grant
- 2013-09-03 PL PL13762666T patent/PL2892891T3/en unknown
- 2013-09-03 KR KR1020157005961A patent/KR101692707B1/en active Active
- 2013-09-03 JP JP2015531142A patent/JP5970134B2/en active Active
- 2013-09-03 EA EA201500298A patent/EA027244B1/en not_active IP Right Cessation
- 2013-09-03 SG SG10201510668UA patent/SG10201510668UA/en unknown
- 2013-09-03 MA MA37891A patent/MA37891B1/en unknown
- 2013-09-03 GE GEAP201313783A patent/GEP20176631B/en unknown
- 2013-09-03 LT LTEP13762666.9T patent/LT2892891T/en unknown
- 2013-09-03 ES ES13762666T patent/ES2748798T3/en active Active
- 2013-09-03 CA CA2880494A patent/CA2880494C/en active Active
- 2013-09-03 PE PE2015000295A patent/PE20151001A1/en active IP Right Grant
- 2013-09-03 NZ NZ703989A patent/NZ703989A/en unknown
- 2013-09-03 RS RSP20191306 patent/RS59394B1/en unknown
- 2013-09-03 US US14/016,452 patent/US8906904B2/en not_active Ceased
- 2013-09-03 AP AP2015008231A patent/AP2015008231A0/en unknown
- 2013-09-03 SI SI201331583T patent/SI2892891T1/en unknown
- 2013-09-03 SG SG11201500861QA patent/SG11201500861QA/en unknown
- 2013-09-03 AU AU2013312931A patent/AU2013312931B2/en active Active
- 2013-09-06 UY UY0001035012A patent/UY35012A/en active IP Right Grant
- 2013-09-06 TW TW102132286A patent/TWI586661B/en active
- 2013-09-06 AR ARP130103197A patent/AR092869A1/en active IP Right Grant
-
2015
- 2015-01-29 IL IL236987A patent/IL236987A/en active IP Right Grant
- 2015-02-03 CL CL2015000255A patent/CL2015000255A1/en unknown
- 2015-02-18 TN TNP2015000054A patent/TN2015000054A1/en unknown
- 2015-03-03 PH PH12015500457A patent/PH12015500457B1/en unknown
- 2015-03-06 CL CL2015000562A patent/CL2015000562A1/en unknown
- 2015-04-02 EC ECIEPI201512804A patent/ECSP15012804A/en unknown
-
2016
- 2016-10-31 US US15/338,605 patent/USRE46886E1/en active Active
-
2019
- 2019-10-22 CY CY20191101099T patent/CY1122610T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236987A (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| IL223259A0 (en) | Soluble guanylate cyclase activators | |
| EP2632551A4 (en) | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | |
| EP3079700A4 (en) | Soluble guanylate cyclase activators | |
| EP3079701A4 (en) | Soluble guanylate cyclase activators | |
| SI2882734T1 (en) | Dihydropyridone as factor xia inhibitors | |
| PL2912041T3 (en) | Tetrahydropyrrolothiazine derivatives as bace inhibitors | |
| AP2014008044A0 (en) | Pyrazole compounds as SGLT1 inhibitors | |
| IL236362A (en) | Arylethynyl derivatives | |
| SG11201404325VA (en) | Pyrimidooxazocine derivatives as mtor - inhibitors | |
| ZA201501678B (en) | Arylethynyl derivatives | |
| GB201219296D0 (en) | Pyrazole derivatives | |
| GB201219289D0 (en) | Pyrazole derivatives | |
| GB201218245D0 (en) | Pyrazole derivatives | |
| ZA201103204B (en) | Phenylpyrazole derivatives | |
| AU346446S (en) | Packaging for outdoor accessory | |
| GB201203149D0 (en) | Tea bag additives |